ImmunityBio Stock Rises on Accelerated Approvals from Saudi Regulators for Anktiva Treatment

Dow Jones

Yesterday

By Kelly Cloonan

Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment.

The stock rose 6.6% to $3.01 on Wednesday. Shares are up 28% in the last 12 months.

The immunotherapy company said it received accelerated approval from the the Saudi Food and Drug Authority for Anktiva to treat non-muscle invasive bladder cancer and metastatic non-small cell lung cancer.

The company also plans to open a regional office in Saudi Arabia to support its expansion in the Middle East and North Africa. It plans to work with Biopharma Cigalah as its commercial and distribution partner in the region.

Bladder and lung cancers have grown more common in the region, posing a need for further treatment options, Chief Executive Rich Adcock said.

"We are pursuing approvals across the region to fill that need," Adcock said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

January 14, 2026 11:14 ET (16:14 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603485976"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603485976\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603485976?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603485976","market":"sh","top_or_hot":-1,"title":"ImmunityBio Stock Rises on Accelerated Approvals from Saudi Regulators for Anktiva Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment. \n</p>\n<p>\n  The stock rose 6.6% to $3.01 on Wednesday. Shares are up 28% in the last 12 months. \n</p>\n<p>\n  The immunotherapy company said it received accelerated approval from the the Saudi Food and Drug Authority for Anktiva to treat non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. \n</p>\n<p>\n  The company also plans to open a regional office in Saudi Arabia to support its expansion in the Middle East and North Africa. It plans to work with Biopharma Cigalah as its commercial and distribution partner in the region. \n</p>\n<p>\n  Bladder and lung cancers have grown more common in the region, posing a need for further treatment options, Chief Executive Rich Adcock said. \n</p>\n<p>\n  \"We are pursuing approvals across the region to fill that need,\" Adcock said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2026 11:14 ET (16:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Stock Rises on Accelerated Approvals from Saudi Regulators for Anktiva Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Stock Rises on Accelerated Approvals from Saudi Regulators for Anktiva Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-15 00:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment. \n</p>\n<p>\n  The stock rose 6.6% to $3.01 on Wednesday. Shares are up 28% in the last 12 months. \n</p>\n<p>\n  The immunotherapy company said it received accelerated approval from the the Saudi Food and Drug Authority for Anktiva to treat non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. \n</p>\n<p>\n  The company also plans to open a regional office in Saudi Arabia to support its expansion in the Middle East and North Africa. It plans to work with Biopharma Cigalah as its commercial and distribution partner in the region. \n</p>\n<p>\n  Bladder and lung cancers have grown more common in the region, posing a need for further treatment options, Chief Executive Rich Adcock said. \n</p>\n<p>\n  \"We are pursuing approvals across the region to fill that need,\" Adcock said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2026 11:14 ET (16:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603485976","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603485976","pubTimestamp":1768407240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment.The stock rose 6.6% to $3.01 on Wednesday. Shares are up 28% in the last 12 months.The immunotherapy company said it received accelerated approval from the the Saudi Food and Drug Authority for Anktiva to treat non-muscle invasive bladder cancer and metastatic non-small cell lung cancer.The company also plans to open a regional office in Saudi Arabia to support its expansion in the Middle East and North Africa. It plans to work with Biopharma Cigalah as its commercial and distribution partner in the region.Bladder and lung cancers have grown more common in the region, posing a need for further treatment options, Chief Executive Rich Adcock said.\"We are pursuing approvals across the region to fill that need,\" Adcock said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc."},"translate_title":"ImmunityBio股价因沙特监管机构加速批准Anktiva治疗而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment. \n\n\n  The stock rose 6.6% to $3.01 on Wednesday. Shares are up 28% in the last 12 months. \n\n\n  The immunotherapy company said it received accelerated approval from the the Saudi Food and Drug Authority for Anktiva to treat non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. \n\n\n  The company also plans to open a regional office in Saudi Arabia to support its expansion in the Middle East and North Africa. It plans to work with Biopharma Cigalah as its commercial and distribution partner in the region. \n\n\n  Bladder and lung cancers have grown more common in the region, posing a need for further treatment options, Chief Executive Rich Adcock said. \n\n\n  \"We are pursuing approvals across the region to fill that need,\" Adcock said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 14, 2026 11:14 ET (16:14 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}